Up­dat­ed: FDA ap­proves Ake­bi­a's ane­mia drug af­ter say­ing no in 2022

The FDA on Wednes­day green­lit Ake­bia Ther­a­peu­tics’ treat­ment for ane­mia due to chron­ic kid­ney dis­ease, mark­ing a turn­around for vadadu­s­tat, which the FDA re­ject­ed al­most two years ago to the day over safe­ty con­cerns.

The Cam­bridge, MA-based biotech will mar­ket vadadu­s­tat as Vaf­seo. The once-dai­ly tablets are in­di­cat­ed for adult pa­tients who have been on dial­y­sis for at least three months.

The pre­scrib­ing la­bel comes with a black box warn­ing for in­creased risk of death, my­ocar­dial in­farc­tion, stroke, ve­nous throm­boem­bolism and throm­bo­sis of vas­cu­lar ac­cess.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER